FT
BCRX icon

Fiduciary Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fiduciary Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Hold
42,955
– – ﹤0.01% 643
2026
Q1 		$409K Buy
42,955
+5,702
+15% +$44.3K ﹤0.01% 640
2025
Q4 		$291K Buy
37,253
+11,234
+43% +$81.2K ﹤0.01% 727
2025
Q3 		$197K Hold
26,019
– – ﹤0.01% 827
2025
Q2 		$233K Hold
26,019
– – ﹤0.01% 757
2025
Q1 		$195K Buy
+26,019
New +$210K ﹤0.01% 790

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Fiduciary Trust's BCRX Position: Q2 2026 in Review

Fiduciary Trust held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 42,955 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #643.

Fiduciary Trust first reported a position in BCRX in Q1 2025 and has held it in 6 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Fiduciary Trust held 42,955 shares of BioCryst Pharmaceuticals worth $430K as of Q2 2026.
  • Fiduciary Trust left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #643 holding.
  • Fiduciary Trust first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.